With continuous progress of life science, practical applications of next-generation biopharmaceuticals with new therapeutics modalities(1) demonstrating better balance of efficacy and side-effect, such as genes-, cell-, and mRNA(2)- therapeutics, have been recognized. Those new drug discovery modalities are also contributing to the speedy and variety development of vaccines and therapeutics for COVID-19.
On the other hand, next-generation biopharmaceuticals are more expensive to develop and manufacture than low-molecular-weight pharmaceuticals, and due to their nature, the product stability and effective period and product life are shorter, and it would be better to develop and manufacture products with small quantity and high variety. Manufacturing costs and risks tend to be high.
Through this collaboration, Hitachi and Axcelead will develop solutions that support the more efficient creation of next-generation biopharmaceuticals with digital technology and drug discovery platforms, and also support entities that participate in this field. In addition, the both companies will jointly promote the development of specialized human resources who are familiar with the development and manufacturing of next-generation biopharmaceuticals.
Hitachi, with over 100 years deep experience in manufacturing industry, has provided many companies with variety of solutions utilizing Lumada, which accelerates digital innovation by combining OT, IT, and products. In the field of regenerative medicine, Hitachi provides automated cell culture equipment for iPS cells, cell processing facilities, manufacturing execution systems, biosafety cabinets, etc., to pharmaceutical companies and research institutes according to customer needs.
Axcelead is a drug desicovery platform company group, having its core company,
Hitachi and Axcelead aim to contribute to improving QoL (Quality of Life) for human through medical innovation with next-generation biopharmaceuticals.
(1) Therapeutics modality: A general term for the mechanism of action, materials, and treatment methods of drugs.
(2) mRNA: Abbreviation for messenger RNA, a blueprint for making proteins. It is made from DNA in the cell's nucleus and is degraded shortly after it is used to make proteins.
(3) CDMO (
(4) DDS (Drug Delivery System): A technology aimed at maximizing the effects of drugs and minimizing side effects by controlling the distribution of drugs in the body.
About
About
Axcelead is a group of companies that develops a drug discovery platform business centered on ADDP,
Copyright 2021 JCN Newswire . All rights reserved.
© Japan Corporate News, source